PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant/refractory disease and frequent prior ...
The safety population consisted of 109 patients treated with at least one dose of rezatapopt 2000 mg daily as monotherapy. Median number of prior lines of systemic therapy was three (range: 1-10) The ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across ...
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
PMV Pharmaceuticals Inc.’s rezatapopt yielded impressive overall response data in ovarian cancer, prompting the firm to aim for a potential accelerated approval filing in early 2027. The news caused ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results